Skip to content
Review Open access

Efficacy and Safety of Dual GLP‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis

Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11872 - 11890 · 0 citations · 42 references
Medicine

Abstract

Dual glucagon‐like peptide‐1/glucagon receptor (GLP‐1/GCGR) agonists represent a novel obesity treatment class, but existing meta‐analyses often conflate them with GIP‐containing agents (tirzepatide, retatrutide) or restrict analysis to one or two drugs, leaving class‐specific efficacy and safety incompletely characterized.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.